Clinical TrialMay 26, 2026, 07:02 AM
Jade Biosciences Doses First Patient in Phase 2 IgAN Trial for JADE101
AI Summary
Jade Biosciences announced the dosing of the first participant in its Phase 2 JUNIPER trial for JADE101, targeting immunoglobulin A nephropathy (IgAN). JADE101 is a clinical-stage therapy designed to block APRIL, a key driver of pathogenic IgA production in IgAN, a chronic autoimmune kidney disease affecting approximately 169,000 people in the U.S. Interim data from the JUNIPER trial, which will evaluate JADE101 in approximately 30 participants, are anticipated in 2027. Preclinical data suggest JADE101 has ultra-high binding affinity and a differentiated profile supporting infrequent subcutaneous dosing.
Key Highlights
- First participant dosed in Phase 2 JUNIPER trial for JADE101 in IgAN.
- Interim data from the JUNIPER trial are expected in 2027.
- JUNIPER is an open-label Phase 2 clinical trial with approximately 30 participants.
- JADE101 is designed to selectively block APRIL, a key driver of IgA production.
- IgA nephropathy (IgAN) affects approximately 169,000 people in the U.S.
- Preclinical data showed JADE101 has a serum half-life of approximately 27 days.
- JADE101 supports potential for subcutaneous dosing no more frequently than every eight weeks.
Price Impact
More from JBIO